Ritlecitinib in Alopecia Areata: A 24-Week Real-World Experience Contrasting JAK Inhibitor-Naïve and JAK...

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Alopecia areata (AA) is an autoimmune condition causing non-scarring hair loss.
• Baricitinib has improved AA treatment, but some severe cases remain refractory.
• Ritlecitinib is a new oral dual JAK3/TEC kinase inhibitor approved for severe AA.

Purpose of the Study:

• To evaluate the real-world outcomes and safety of ritlecitinib in severe AA patients.
• To compare ritlecitinib's effectiveness in JAK inhibitor (JAKi)-naïve versus JAKi-experienced patients, particularly those previously treated with baricitinib.

Main Methods:

• A retrospective, single-center study of 22 severe AA patients treated with ritlecitinib 50 mg daily for 24 weeks.
• Patients were categorized into JAKi-naïve (n=9) and JAKi-experienced (n=13, previously on baricitinib) groups.
• Efficacy assessed by SALT score reduction (SALT50, SALT75) and safety by adverse events.

Main Results:

• JAKi-naïve patients were younger and had shorter AA duration than JAKi-experienced patients.
• All JAKi-naïve patients achieved SALT50, with 78% reaching SALT75.
• In JAKi-experienced patients, 23% achieved SALT50 and 8% reached SALT75, with 54% showing any SALT score reduction.
• No treatment-related adverse events or disease worsening were observed in either group.

Conclusions:

• Ritlecitinib is highly effective in adolescent JAKi-naïve severe AA patients.
• While less effective in patients previously treated with baricitinib, switching to ritlecitinib is a safe therapeutic option with a low risk of exacerbation.